Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | UGT2B7 | P16662 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL813343 | 1.00 | PTPN2 (0.43) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL813342 | 1.00 | PTPN2 (0.43) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL10971244 | 1.00 | PTPN2 (0.43) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL9617991 | 1.00 | PTPN2 (0.43) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL813344 | 1.00 | PTPN2 (0.43) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL813341 | 1.00 | PTPN2 (0.43) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL954543 | 0.86 | UGT2B7 (0.52) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL9248576 | 0.86 | UGT2B7 (0.52) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL954950 | 0.86 | UGT2B7 (0.52) | PTPN2PTPN1UGT2B7 | |
| SCHEMBL954542 | 0.86 | UGT2B7 (0.52) | PTPN2PTPN1UGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023204775-A1 | HERBAL PRODUCT FOR USE IN THE PREVENTION AND/OR TREATMENT OF COVID-19 | IPMC GROUP ILAC SAN. VE TIC. LTD. STI. (TR) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023204776-A1 | HERBAL PRODUCT FOR USE IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR DISEASES | IPMC GROUP ILAC SAN. VE TIC. LTD. STI. (TR) | 2023-10-26 | — | — | WO | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| WO-2017174109-A1 | HERBAL PRODUCT FOR TREATMENT OF DIABETES MELLITUS | ALZANDANI ABDULMAJEED AZIZ (YE) | 2017-10-12 | — | — | WO | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011039574-A1 | THE USE OF A HERBAL COMPOSITION FOR THE TREATMENT OF A PERSON INFECTED WITH HIV | VAN DER WALT, LOUIS, STEPHANUS (ZA) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | PTPN2 768/4885PTPN1 725/4885UGT2B7 2215/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | PTPN2 768/4885PTPN1 725/4885UGT2B7 2215/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | PTPN2 768/4885PTPN1 725/4885UGT2B7 2215/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | PTPN2 768/4885PTPN1 725/4885UGT2B7 2215/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | PTPN2 768/4885PTPN1 725/4885UGT2B7 2215/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | PTPN2 768/4885PTPN1 725/4885UGT2B7 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.